Disease markers play an important role in patient care. 1, 2 Diagnostic markers can be used for detecting diseases, predicting response to a therapy, making prognosis for a patient, or estimating the outcome of a treatment. Despite great progress in instrumentation and analytical techniques, few new biomarkers have been discovered during the past decade. Some reasons for slow progress are the low throughput of analysis, high false discovery rate, lack of data on verification of the discovered potential biomarkers, and poor stability of many biomolecules.
Human blood contains enzymes and proteases, which alter proteins in vivo and in vitro. Studies have suggested that many peptides identified in biological samples are generated by proteolytic cleavage of plasma proteins, which are subsequently altered by peptidases. 3, 4 Some of the degradation takes place in vivo, while many of the products could be generated in vitro during blood collection and sample storage. Considering this, peptides identified in the biomarker discovery experiments could be intermediates of sequential reactions, which are unstable over time and could arise from biological variability related to sample collection or handling, or be detected because of technical variability during the analysis. 5, 6 It is known that the stability of many proteins differs between serum and plasma samples collected in tubes with different types of anticoagulants. Differences associated with different sample types are associated with inhibition of the endogenous proteases by anticoagulants, which reduce activity of the proteases. Residual plasma protease and peptidase activity results in time-dependent variations and instability of the samples, especially during sample collection and processing. Results of a study by Yi et al 7 suggest that mixing protease inhibitors with blood immediately during blood collection results in enhanced stabilization of plasma proteome.
Proteases can be subdivided into 4 classes: serine, cysteine, aspartic, and metalloproteases. Peptidases belong to 1 of 3 classes: endo-, exo-, and carboxypeptidases. In vivo, proteins are either protected from proteolysis in specialized compartments or reside in a protective conformation. When proteins are isolated from cells, there is a potential for their degradation via proteolytic enzymes. Protease inhibitors (PIs) are often used in experimental protocols to protect proteins from degradation. More than 100 naturally occurring PIs have been identified and can be used during the sample collection to prevent protein degradation.
Monitoring and controlling preanalytical variations have a major impact on the success of work in biomarker discovery and verification. In this issue of the Journal, Findeisen et al 8 assess the exposure of serum and plasma samples to suboptimal storage conditions. Considering that the outcome of experiments is affected by protein stability, the authors suggest determining the preanalytical quality of serum and plasma by monitoring the time-dependent decay of a synthetic reporter peptide (RP) added to the samples at the time of sample collection. In the study, serum and plasma specimens were spiked with the RP, and proteolytic fragments were monitored at different time points up to 24 hours after blood sample collection. In the proposed method, analysis of the RP and its degradation product was performed by liquid chromatography/mass spectrometry. The sequence of the RP and the monitored fragments were selected with a goal of having properties, allowing time-dependent degradation of the RP with accumulation of stable RP. Quantitative measurement of the RP was shown to enable monitoring of the preanalytical time span of the samples' exposure to conditions associated with increased activity of proteases. Using a set of test samples (n = 30), the authors demonstrated accuracy of the approach by assessing area under the receiver operating characteristic curve (AUROC = 0.89). Findeisen et al suggested use of the RP as a "proteomic degradation clock" (PDC) for estimating the preanalytical exposure of serum and plasma samples to inadequate storage conditions.
Considering the diversity of analytical applications, PDC should be used only when its use fits the purpose (eg, samples collected for biomarker discovery or as quality control for biobanking repositories). When a potential biomarker is already identified, evaluation of the general sample degradation will not be helpful; in this case, the goal should be to find storage and handling conditions at which the marker will be sufficiently stable for practical use in the intended application.
Investigation of the instability of plasma proteins and peptides due to proteolysis and subsequent sample preparation has been the subject of many studies. 5, [9] [10] [11] Yi et al 7 demonstrated that many plasma proteins degrade within minutes of sample collection, suggesting rapid proteolytic degradation of the blood proteins and peptides by endogenous proteases and peptidases.
To enhance sample stability and reduce protein degradation, blood can be collected in tubes containing an individual PI or cocktails of PIs. Ideally, blood should be mixed with PIs immediately during the blood draw, allowing to immediately inhibit proteolytic degradation. In many cases, inhibitors do not completely prevent proteolysis but minimize time-dependent changes after a blood draw, which could enable use of unstable protein or peptide as a biomarker.
Considering the work of Findeisen et al 8 as an approach for ensuring sample integrity, one needs to remember that many changes with sample constituents take place at the time of the blood draw; because properties of different proteins are unique, no single universal marker would be representative of the stability of all potential biomarkers in complex biological samples. Because individual patient samples may have an elevated concentration of some proteases or inhibitors, in such samples the PDC could be "too fast" to "too slow."
Considering the large diversity in stability among endogenous proteins, in some cases PDC could also be misleading in the assessment of the general sample stability. In the article, Findeisen et al 8 address only exposure to room temperature, but a number of other factors could affect stability of individual proteins (effect of diseases, interindividual variability, presence of impurities introduced during manufacturing of the consumables, or use of protein inhibitors during the sample collection, etc).
Considering that PDC by itself is the subject of analytical measurements and that it is added to highly complex biological samples at a low concentration, its measurement could be a challenge. The same performance characteristics expected from mass spectrometry-based methods for the measurement of diagnostic biomarkers (high accuracy of measurements, low within-and between-day imprecision, sufficient sensitivity and linearity, good agreement with a reference method and methods of other laboratories, and absence of interferences and ion suppression, etc) should be assessed for the PDC prior to its introduction in routine use. Methods for measuring PDC should undergo rigorous validation, use calibration standards and stable isotope-labeled analogues of PDC (used as an internal standard), and have appropriate quality control materials. If good analytical practices will not be followed or testing of the PDC would require additional freeze/defrost cycles or excessive sample exposure to a suboptimal temperature, utility of the PDC could be questionable.
